ArticleStem cells international2011
Could metabolic syndrome, lipodystrophy, and aging be mesenchymal stem cell exhaustion syndromes?
Article in Stem cells international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts.Cancer research · 2021Pooled it
- Evaluation of the efficacy of FDG-PET/CT in assessing the effects of BMMSC treatment in aged rhesus monkeys.Stem cell research & therapy · 2025Article
- Obesity, Metabolic Syndrome, and Osteoarthritis Require Integrative Understanding and Management.Biomedicines · 2024Review
- The Bone Marrow Microenvironment in Immune-Mediated Inflammatory Diseases: Implications for Mesenchymal Stromal Cell-Based Therapies.Stem cells translational medicine · 2024Review
- Article
- The promising role of autologous and allogeneic mesenchymal stromal cells in managing knee osteoarthritis. What is beyond Mesenchymal stromal cells?Journal of clinical orthopaedics and trauma · 2022Review
- Advantages and challenges of stem cell therapy for osteoarthritis (Review).Biomedical reports · 2021Review
- CXCL2 Impairs Functions of Bone Marrow Mesenchymal Stem Cells and Can Serve as a Serum Marker in High-Fat Diet-Fed Rats.Frontiers in cell and developmental biology · 2021Article
- Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses.Cellular and molecular life sciences : CMLS · 2021Review
- Hepatic stellate cell-specific knockout of transcriptional intermediary factor 1γ aggravates liver fibrosis.The Journal of experimental medicine · 2020Article
- Article
- Major depression and enhanced molecular senescence abnormalities in young and middle-aged adults.Translational psychiatry · 2019Article
- Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities.International journal of molecular sciences · 2019Review
- Dysregulation of Mesenchymal Stromal Cell Antioxidant Responses in Progressive Multiple Sclerosis.Stem cells translational medicine · 2018Article
- High-Dimensional Phenotyping Identifies Age-Emergent Cells in Human Mammary Epithelia.Cell reports · 2018Article
- Effect of aging on stem cells.World journal of experimental medicine · 2017Review
- Aging and adipose tissue: potential interventions for diabetes and regenerative medicine.Experimental gerontology · 2016Review
- A Rat Treated with Mesenchymal Stem Cells Lives to 44 Months of Age.Rejuvenation research · 2016Article
- Adult Stem Cells and Diseases of Aging.Journal of clinical medicine · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most important and complex diseases of modern society is metabolic syndrome. This syndrome has not been completely understood, and therefore an effective treatment is not available yet. We propose a possible stem cell mechanism involved in the development of metabolic syndrome. This way of thinking lets us consider also other significant pathologies that could have similar etiopathogenic pathways, like lipodystrophic syndromes, progeria, and aging. All these clinical situations could be the consequence of a progressive and persistent stem cell exhaustion syndrome (SCES). The main outcome of this SCES would be an irreversible loss of the effective regenerative mesenchymal stem cells (MSCs) pools. In this way, the normal repairing capacities of the organism could become inefficient. Our point of view could open the possibility for a new strategy of treatment in metabolic syndrome, lipodystrophic syndromes, progeria, and even aging: stem cell therapies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.